Actively Recruiting
Observational Study to Characterize Patients With COPD on Dupilumab Treatment and Assess Long-term Safety and Patient Outcomes
Led by Sanofi · Updated on 2026-09-21
500
Participants Needed
28
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a non-interventional observational study to follow patients with Chronic Obstructive Pulmonary Disease COPD who are treated with dupilumab as part of their usual medical care. The study aims to describe patient characteristics, assess safety, and evaluate patient-reported outcomes over a long-term period. This study will include about 350 to 500 participants across up to 50 sites in France. Participants will be observed for approximately 36 months without altering their routine treatment. The study collects data retrospectively and prospectively on patients newly started on dupilumab for COPD, as determined by their treating physician according to approved guidelines. There is no randomization or placebo group since this is an observational study. During the study, participants medical records and clinical data will be reviewed regularly to analyze demographics, disease history, treatment history, lung function, symptom assessments, and exacerbation rates. Researchers will track changes in lung function tests, COPD assessment scores, hospitalizations, adverse events, and reasons for treatment discontinuation over three years. Participants will not have to undergo additional treatments, but their health will be monitored as part of this long-term observational study.
CONDITIONS
Brief Title
Long-term Real-world Study of Dupilumab in COPD : Patient Characteristics, Safety and Patient-reported Outcomes
Research Team
T
Trial Transparency email recommended (Toll free for US & Canada)
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here